Testosterone Cypionate vs AndroGel Side-Effect Profile: Head-to-Head

What Are These Two Testosterone Formulations?

Testosterone cypionate and AndroGel are both FDA-approved testosterone-replacement therapies for hypogonadism in men, but they work through entirely different delivery routes. Cypionate is an esterified testosterone dissolved in cottonseed oil, administered by intramuscular or subcutaneous injection. AndroGel delivers testosterone transdermally through a hydroalcoholic gel applied to shoulders, upper arms, or abdomen each morning.

Testosterone Cypionate: Basics

The FDA first approved testosterone cypionate in 1979 [1]. Standard dosing runs 100 to 200 mg every 7 to 14 days by intramuscular injection, though many clinicians now prescribe 50 to 70 mg weekly by subcutaneous injection to reduce hormonal peaks and troughs. The cypionate ester extends the half-life of testosterone to roughly 8 days, meaning serum levels peak 24 to 48 hours after injection and then decline steadily until the next dose [2].

AndroGel: Basics

AndroGel 1% received FDA approval in 2000, and AndroGel 1.62% followed in 2011 [3]. Applied once daily, the gel delivers testosterone through the skin over a 24-hour period, producing relatively stable serum concentrations compared with every-14-day injection cycles. The prescribing information for AndroGel 1.62% lists a starting dose of 40.5 mg (2 pump actuations) titrated up to a maximum of 103.25 mg (5 pump actuations) based on morning serum testosterone drawn 14 days after initiation [3].

Side-Effect Profile: Testosterone Cypionate

Injection-Site Reactions

The most common adverse events specific to cypionate are local. Pain at the injection site, erythema, and induration affect a meaningful proportion of users, the FDA label reports injection-site reactions in up to 9% of patients in clinical evaluation periods [2]. Subcutaneous injection technique, now preferred by many TRT prescribers, tends to reduce deep-tissue discomfort compared with intramuscular administration, though oil-based vehicles can still cause temporary nodules.

Hormonal Peaks and Troughs

Every-14-day dosing creates the steepest peak-to-trough swings. Serum testosterone may reach 1,200 to 1,500 ng/dL in the 48 hours after a 200 mg injection, then fall to 300 ng/dL or below just before the next dose [2]. These swings can produce mood variability, energy crashes, and libido fluctuations that patients often describe as a "roller coaster." Shortening the interval to weekly or twice-weekly dosing substantially narrows this fluctuation [4].

Polycythemia and Cardiovascular Considerations

Erythrocytosis (hematocrit above 54%) is the most clinically significant laboratory finding associated with injectable testosterone. A 2023 analysis from the TRAVERSE trial (N=5,246, mean age 63.3 years) found that testosterone therapy increased the incidence of high hematocrit readings compared with placebo, with a statistically meaningful difference emerging by month 12 [5]. The Endocrine Society Clinical Practice Guideline recommends checking hematocrit at baseline, at 3 to 6 months, and annually thereafter, and reducing dose or extending the injection interval if hematocrit exceeds 54% [6].

Estradiol Conversion

Testosterone converts to estradiol via the aromatase enzyme. Higher peak testosterone levels after injection drive proportionally higher peak estradiol, which can contribute to gynecomastia and fluid retention in susceptible men [7]. Monitoring serum estradiol at the same time as total testosterone helps distinguish aromatase excess from other causes.

Side-Effect Profile: AndroGel

Skin and Local Reactions

Contact dermatitis, application-site dryness, and pruritus are the most common local adverse events with AndroGel. The prescribing information for AndroGel 1.62% cites application-site reactions in approximately 4% of users in controlled trials [3]. Rotating application sites and allowing the gel to dry fully before dressing reduces skin irritation in most patients.

Secondary (Skin-to-Skin) Transfer

This is the side-effect category that has no equivalent with injections. Secondary transfer of testosterone to female partners and children through skin contact has been documented in FDA MedWatch reports and in the AndroGel label itself, prompting a black-box warning [3]. Children exposed to transferred testosterone may develop premature pubic hair, clitoral or penile enlargement, and advanced bone age, changes that may be only partially reversible [8]. The FDA reinforced this warning after reviewing cases in 2009 [8]. Patients must cover application sites with clothing or wash skin thoroughly before contact, for a minimum of 2 to 5 hours post-application.

Hormonal Stability

Daily application produces flatter diurnal testosterone curves than every-14-day injections. The T-Trials (N=788 men aged 65 or older with confirmed hypogonadism, serum testosterone <275 ng/dL) demonstrated that topical testosterone raised mean serum testosterone into the normal range (400 to 800 ng/dL) after 12 months of daily gel use, with a relatively stable concentration profile across measurement time points [9]. This stability reduces the mood and energy fluctuations seen with longer injection intervals.

Skin Absorption Variability

A practical limitation of gels is inter-individual absorption variability. Factors including skin hydration, ambient temperature, application-site thickness, and use of sunscreen at the application site can all alter the amount of testosterone that reaches systemic circulation [10]. Two men applying the same AndroGel dose may end up with substantially different serum testosterone levels, requiring more frequent dose titration.

Direct Comparison: Key Side-Effect Categories

The table below organizes the most clinically relevant adverse effects by formulation. No head-to-head randomized controlled trial has directly compared cypionate injections with AndroGel in a single parallel-arm design; the comparisons below synthesize data from individual product labels, the T-Trials, and published pharmacokinetic studies.

| Side-Effect Category | Testosterone Cypionate | AndroGel | |---|---|---| | Injection-site reactions | Up to 9% (label) | Not applicable | | Secondary transfer | Not applicable | Black-box warning; documented pediatric cases | | Skin/application-site reactions | Not applicable | ~4% in controlled trials | | Peak-trough T swing (14-day dosing) | Wide (up to 1,200+ ng/dL peak) | Narrow (stable daily delivery) | | Polycythemia risk | Elevated; monitor Hct q3-6 months | Present but may be lower with stable levels | | Estradiol elevation | Higher at peak; may need monitoring | Lower peak; less fluctuation | | Mood/energy variability | Common with 14-day intervals | Less common with daily gel | | Convenience | Weekly or biweekly injections required | Daily application; travel-friendly | | Transfer risk to household members | None | Significant; black-box warning |

What the T-Trials Tell Us

The Testosterone Trials, published in the New England Journal of Medicine in 2016 (N=788), remain the largest placebo-controlled dataset examining testosterone therapy specifically in older men with age-associated hypogonadism [9]. The trial used daily testosterone gel (not injections) as the active comparator. Key findings relevant to side effects:

• Hematocrit rose by an average of 3.0 percentage points in the testosterone group versus 0.7 percentage points in the placebo group over 12 months (P<0.001) [9].
• Cardiovascular event rates did not differ significantly between groups in this 12-month trial, though the study was not powered to detect differences in major adverse cardiovascular events.
• PSA rose by a mean of 0.30 ng/mL in the testosterone group versus 0.07 ng/mL in placebo (P<0.001) [9].

The Endocrine Society guideline directly cites the T-Trials when stating: "We suggest measuring hematocrit before initiating testosterone therapy, at 3 to 6 months, and then annually" [6]. Because the T-Trials used gel, these polycythemia figures specifically apply to AndroGel-class products; injectable testosterone may carry an equal or greater erythrocytosis risk given higher peak concentrations [5].

Polycythemia: The Side Effect Both Formulations Share

Polycythemia deserves dedicated attention because it is the adverse effect most likely to require dose adjustment or therapy discontinuation regardless of formulation. Hematocrit above 54% increases whole-blood viscosity and raises the theoretical risk of venous thromboembolism [11].

Monitoring Protocol

The Endocrine Society recommends hematocrit checks at baseline, 3 months, 6 months, and then every 12 months on stable therapy [6]. The AACE similarly advises that a hematocrit exceeding 54% should trigger a dose reduction, formulation switch, or temporary discontinuation until levels normalize [12].

Injection vs. Gel Risk

Published pharmacokinetic data suggest that injection-related supraphysiologic testosterone peaks drive erythropoietin stimulation more intensely than the stable levels produced by daily gel [4]. A 2019 review in the Journal of Clinical Endocrinology and Metabolism found that polycythemia rates in injection-treated cohorts ran approximately 6 to 8%, compared with 2 to 4% in transdermal-treated groups, though direct head-to-head RCT data remain limited [4].

Cardiovascular and Thrombosis Signal

The TRAVERSE trial (N=5,246), published in the New England Journal of Medicine in 2023, was specifically designed to assess cardiovascular safety of testosterone therapy in middle-aged and older men with hypogonadism and high cardiovascular risk [5]. The trial used daily testosterone gel. TRAVERSE found non-inferiority for major adverse cardiovascular events (MACE) compared with placebo over a median follow-up of 33 months, which led the FDA to update testosterone labeling to remove the prior blanket cardiovascular warning [13].

Atrial fibrillation was numerically higher in the testosterone arm (3.5% vs. 2.4%), and acute kidney injury was also higher (2.3% vs. 1.5%) [5]. Pulmonary embolism rates did not differ significantly. Because TRAVERSE used gel, these event rates cannot be applied directly to cypionate injections without adjustment for the different pharmacokinetic profile.

The FDA's current prescribing guidance states that "testosterone products are not recommended for use in men with a history of recent myocardial infarction or cerebrovascular accident" [13].

Estradiol, Gynecomastia, and Mood

Aromatization Differences

Testosterone aromatizes to estradiol in peripheral adipose tissue. Higher peak testosterone levels following cypionate injection translate into transient estradiol spikes that can cause nipple tenderness, breast tissue proliferation, and fluid retention in men with higher adiposity or genetic aromatase activity [7]. AndroGel, by maintaining a flatter testosterone curve, produces a more stable estradiol level, which some men find reduces gynecomastia symptoms compared with every-14-day injections [10].

Mood Fluctuation

Men who self-report mood variability on every-14-day cypionate dosing often describe irritability and fatigue in the 2 to 3 days before their next injection, the so-called "trough effect." Switching to weekly or twice-weekly smaller cypionate doses, or transitioning to daily gel, frequently resolves this pattern. A 2016 pharmacokinetic analysis found that 100 mg cypionate weekly produced peak-trough ratios roughly 40% narrower than 200 mg every 14 days [4].

Can You Switch From Testosterone Cypionate to AndroGel?

Switching is clinically straightforward but requires a brief washout or overlap period. Because cypionate has an 8-day half-life, a patient stopping a 100 mg weekly injection and starting AndroGel 1.62% on the same day will have residual injectable testosterone declining over roughly 3 to 4 weeks while gel levels build [2]. Most prescribers start the gel on the day after the last injection would have been due, then check serum total testosterone 14 days into gel use to guide dose titration [3].

The reverse switch (gel to injection) requires no washout because gel clears within 24 to 48 hours of the last application.

Reasons clinicians consider a formulation switch:

• Persistent polycythemia on cypionate (switching to gel may reduce erythrocytosis risk)
• Injection-site complications (cellulitis, phobia)
• Household with young children or a female partner trying to conceive (switching away from gel eliminates transfer risk)
• Patient preference for needle-free administration
• Inconsistent gel absorption requiring frequent dose changes (switching to injection provides more predictable delivery)

Special Populations

Men With Household Children or Female Partners

The black-box transfer warning on AndroGel is not a theoretical concern. The FDA documented multiple pediatric cases of virilization following indirect gel exposure, including cases where a child had no direct contact with the application site but was exposed through a parent's clothing or a shared bed surface [8]. For men living with young children or a partner who is pregnant or breastfeeding, testosterone cypionate injections eliminate this risk entirely.

Older Men (65+)

The T-Trials population (mean age 72.5 years) experienced the polycythemia and PSA increases described above with daily gel. Older men on either formulation warrant more frequent hematocrit and PSA surveillance, as age-related declines in renal clearance and baseline erythropoietin sensitivity may amplify erythrocytosis risk [9].

Men Planning Fertility

Both formulations suppress the hypothalamic-pituitary-gonadal axis, reducing intratesticular testosterone and impairing spermatogenesis. Neither is appropriate for men actively pursuing paternity without concurrent gonadotropin support (typically hCG 500 to 1,500 IU every 2 to 3 days) [6]. This applies equally to cypionate and gel.

Practical Dosing and Monitoring at a Glance

Testosterone Cypionate Monitoring Schedule

1. Baseline: total testosterone (morning), hematocrit, PSA, LH, FSH, estradiol, metabolic panel.
2. Week 6 to 8: total testosterone drawn mid-cycle (3 to 4 days after injection for weekly dosing).
3. Month 3: hematocrit, PSA, estradiol, total testosterone.
4. Month 6: repeat full panel.
5. Annually thereafter on stable dose.

AndroGel Monitoring Schedule

1. Baseline: same as above.
2. Day 14 to 28: morning total testosterone (2 to 8 hours after application) for dose titration.
3. Month 3: hematocrit, PSA, estradiol, total testosterone.
4. Month 6: repeat full panel.
5. Annually thereafter.

The Endocrine Society guideline specifies that for transdermal testosterone, "serum testosterone should be measured 2 to 8 hours after application of the patch or gel" to capture the pharmacokinetic peak accurately [6].

Cost and Access

Testosterone cypionate generic is among the least expensive TRT options in the United States, typically $30, $80 per month for the medication alone, excluding supplies and clinic fees [14]. AndroGel brand carries a substantially higher list price; GoodRx data list AndroGel 1.62% at $400, $600 per month without insurance, though generic testosterone gel 1% is available for $60, $120 per month [14]. Many commercial insurance plans cover both formulations with prior authorization for documented hypogonadism (two morning serum testosterone values <300 ng/dL per Endocrine Society criteria) [6].